发明名称 |
B-cell reduction using CD37-specific and CD20-specific binding molecules |
摘要 |
<p>The present application generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The application further provides materials and methods for application treatment of diseases involving aberrant B-cell activity. In addition, the application provides humanized CD37-specific binding molecules.</p> |
申请公布号 |
EP2586798(A2) |
申请公布日期 |
2013.05.01 |
申请号 |
EP20120185719 |
申请日期 |
2006.07.25 |
申请人 |
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC |
发明人 |
GROSMAIRE, LAURA SUE;LEDBETTER, JEFFREY A.;SIMON, SANDY ALEXANDER;HAYDEN-LEDBETTER, MARTHA SUSAN;THOMPSON, PETER ARMSTRONG;BRADY, WILLIAM |
分类号 |
C07K16/28;A61K39/395;A61P21/04;A61P35/00;A61P37/00;C07K16/46;C12N5/10;C12N15/13;C12N15/85 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|